Neurodegenerative disorders with prominent filamentous alpha-synuclein (alpha-syn) aggregates in CNS neurons or glia are known as synucleinopathies. Synucleinopathies characterized by neuronal alpha-syn inclusions, or Lewy bodies, include Parkinson's disease (PD) and dementia with LBs (DLB), while multiple system atrophy (MSA) is characterized by numerous glial cell inclusions (GCIs) and less frequent LB-like inclusions formed by fibrillar alpha-syn. Most PD is sporadic, but mutations/duplications in the alpha-syn gene of rare kindreds cause autosomal dominant hereditary PD/DLB. Thus, filamentous alpha-syn inclusions are linked to the onset/progression of synucleinopathies. In the current funding cycle, transgenic (TG) mouse models of synucleinopathies were generated that developed neuronal and glial alpha-syn pathologies recapilulating those in DLB and MSA, respectively. We now propose to use these existing TG mice together with new TG mice we will generate to test specific hypotheses regarding toxicity of a-syn and the mechanisms of alpha-syn aggregate formation.
In Aim 1, we will cross our MSA-model TG mice with glial pathology, with those TG mice expressing alpha-syn in neurons, to test the hypothesis that oligodendrocyte degeneration enhances neurodegeneration.
In Aim 2, we will address the significance of dopamine interactions with alpha-syn. Since all TG mice reported to express alpha-syn in neurons do not develop inclusions in dopaminergic substantia nigra (SN) neurons, we hypothesize this is due to dopamine mediated inhibition of alpha-syn fibrillization through interactions with residues 125-127. Now, we propose to test this hypothesis by generating TG mice expressing alpha-syn with these residues mutagenized asking if the removal of the dopamine/alpha-syn interaction facilitates formation of SN alpha-syn neuronal inclusions.
In Aims 3, 4 and 5, we will test the hypotheses that the C-terminus of alpha-syn and Ser129 phosphorylation play important roles in the pathogenesis of alpha-syn lesions and that these lesions induce neurodegeneration in TG by impairing axonal transport. Taken together, our work will lead to more informative models of synucleinopathies and address important questions on mechanisms leading to alpha-syn pathologies and their contribution to brain degeneration in synucleinopathies.
|Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2015) Pattern of extrapyramidal signs in Alzheimer's disease. J Neurol 262:2548-56|
|Paumier, Katrina L; Luk, Kelvin C; Manfredsson, Fredric P et al. (2015) Intrastriatal injection of pre-formed mouse ?-synuclein fibrils into rats triggers ?-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 82:185-199|
|Kalia, Lorraine V; Lang, Anthony E; Hazrati, Lili-Naz et al. (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72:100-5|
|Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405-12|
|Motsinger-Reif, Alison A; Zhu, Hongjie; Kling, Mitchel A et al. (2013) Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun 1:28|
|Arnold, Steven E; Toledo, Jon B; Appleby, Dina H et al. (2013) Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol 521:4339-55|
|Kaddurah-Daouk, R; Zhu, H; Sharma, S et al. (2013) Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry 3:e244|
|Couthouis, Julien; Hart, Michael P; Erion, Renske et al. (2012) Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 21:2899-911|
|Hu, William T; Holtzman, David M; Fagan, Anne M et al. (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79:897-905|
|Chen-Plotkin, Alice S; Unger, Travis L; Gallagher, Michael D et al. (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 32:11213-27|
Showing the most recent 10 out of 208 publications